Moderna Stock News

The U.S. company Moderna has donated 2.7 million doses of coronavirus vaccine to Mexico as the country''s official death toll topped 300,000

Moderna CEO Scrambles To Sell More Boosters As Omicron Wave Shows Signs Of Waning While the rest of the world rejoices at the possibility that the omicron wave might actually bring about the end of the pandemic (while also being bullish for stocks, as we explored earlier in a post about some recent findings out of South Africa ), vaccine makers are already strategizing about how they will convince the world to keep buying boosters when the imminent threat posed by COVID has receded. Speaking at a conference hosted by - who else? - Goldman Sachs, Moderna CEO Stephane Bancel said another round of vaccine boosters will probably be needed this fall, even if immunity to the rapidly spreading omicron does become widespread, like the South African scientists have warned. Bancel added that even if omicron finally causes COVID to become endemic, there will still be a need for people to get their shots, since it''s not clear how long the current wave of immunity will hold. And there''s always uncertainty, since noboody can say for sure what future iterations of SARS-CoV-2 will be like. "Assuming omicron is an acceleration to the endemic phase, I still believe we''re going to need boosters in the fall of 22 and forward," Bancel said during his presentation.

This question could make or break the stock in the years ahead.

Moderna''s CEO Stephane Bancel says its mRNA platform ''can be the answer to a lot of problems.

Amazon.com, Inc (NASDAQ:AMZN), Moderna, Inc

Omicron may move the world rapidly to an endemic phase, said Moderna chief Stephane Bancel.

The efficacy of boosters against Covid-19 is likely to decline and people may need another shot in the fall of 2022, Moderna CEO Stephane Bancel says.

Stephane Bancel, the CEO of vaccine maker Moderna (MRNA) expects that a second COVID-19 booster might be required this fall as the vaccines efficacy decline over the next few

Boosters will likely protect people through the current Omicron surge, Moderna''s Stephane Bancel said. But their efficacy will probably wane in the months ahead.

Moderna CEO says company is working on vaccine to battle Omicron variant of COVID-19, booster may be needed in fall

CNBC carries the report. Moderna CEO Stephane Bancel on Thursday said the efficacy of boosters against Covid-19 will likely decline over time, and people may need a fourth shot in the fall of 2022 to increase their protection. More at that link above. --- ps. Israel is already providing a fo

Finding Chinas answer to Moderna comes with huge health warnings for investors. The $87 billion biotechnology giants Covid-19 vaccines have inspired copycats in the Peoples Republic, where cities like Xian are scrambling to contain fresh outbreaks. With foreign jabs yet to be approved, Shenzhen-listed Walvax Biotechnology and its smaller partner look promising. Their feverish valuations leave little room for error.

Toronto, Jan. 05, 2022 (GLOBE NEWSWIRE) -- North York General Hospital (NYGH), Seneca and the North York Toronto Health Partners are once again partnering to open a COVID-19 vaccination clinic to serve North York residents. Beginning this week, anyone aged 30 or older who is eligible to receive their third dose will be able to book an appointment at the clinic, located at Seneca''s Newnham Campus. "With the rapid spread of Omicron, NYGH and our partners are answering the call to support our community by expanding vaccination," says Karyn Popovich, President and CEO of North York General Hospital. "Thank you to Seneca, fellow members of the North York Toronto Health Partners, and the entire NYGH vaccination team who worked around the clock to make this clinic happen. Getting vaccinated along with our daily safety measures are the most effective ways to protect ourselves and those we love from this tricky virus." Those 30 and over are encouraged to book first and second doses at the NYGH Seneca site clinic as well.

Moderna may have produced one of the worlds biggest medical products in creating an effective vaccine for Covid-19, but it has also landed itself with a problem a bit like the one facing $1.2 trillion electric-vehicle maker Tesla . Modernas market capitalization has rocketed, but only a fraction of its current worth reflects the value of products it actually makes today. The rest is made up of faith in markets yet to exist.